Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities.

Area of Science:

• Immunology
• Oncology
• Pathology

Background:

• Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates found in chronic inflammation, autoimmunity, infections, and cancer.
• TLS share cellular and functional similarities with secondary lymphoid organs and can be associated with favorable outcomes in cancer patients.
• Immune checkpoint inhibitors (ICI) have advanced cancer therapy but have limitations, including resistance and immune-related adverse events (irAEs) that resemble autoimmunity and can involve TLS.

Purpose of the Study:

• To explore the dual role of tumor-associated tertiary lymphoid structures (TA-TLS) in cancer immunotherapy response and irAEs.
• To investigate strategies for manipulating TA-TLS to optimize cancer immunotherapy efficacy and reduce autoimmunity.
• To understand how the tumor microenvironment, specifically TLS, can be modulated for synergistic therapeutic effects.

Main Methods:

• Review of existing literature on TLS, cancer immunology, and immunotherapy.
• Analysis of the correlation between TA-TLS and response to ICI.
• Exploration of potential strategies for modulating TLS, including directed delivery of cytokines, chemokines, and growth factors via vectors.

Main Results:

• TA-TLS are associated with positive responses to immunotherapy but also with increased susceptibility to irAEs.
• The presence and characteristics of TA-TLS suggest a complex interplay between anti-tumor immunity and autoimmunity.
• Strategies targeting TLS composition and function hold promise for enhancing immunotherapy efficacy.

Conclusions:

• TLS represent a critical component of the tumor immune microenvironment with implications for both therapeutic response and adverse events.
• Modulating TLS offers a potential avenue to improve the balance between anti-tumor immunity and self-tolerance in cancer patients treated with immunotherapy.
• Future research should focus on targeted manipulation of TLS to achieve synergistic effects with immunotherapy and minimize irAEs.